STOCK TITAN

Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Prelude Therapeutics Incorporated (Nasdaq: PRLD) is set to participate in two significant healthcare investment conferences in New York City next week. On September 12, CEO Kris Vaddi will engage in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, with one-on-one meetings on September 13. The following day, Vaddi and CMO Dr. Jane Huang will participate in a chat at the Morgan Stanley Global Healthcare Conference, along with additional investor meetings. Prelude is focused on developing innovative oncology drug candidates targeting critical cancer pathways.

Positive
  • None.
Negative
  • None.

WILMINGTON, Del., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare investment conferences next week in New York City.

  • On Monday, September 12, at 1:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference. The live webcast is available here. The company will also be conducting one-on-one meetings with investors on Tuesday, September 13th.

  • On Wednesday, September 14, at 11:10 a.m. ET, Kris Vaddi, Ph.D. and Dr. Jane Huang, President and Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference New York. The live webcast and replay are available here. The company will conduct one-on-one meetings with investors on Wednesday, September 14th.

About Prelude

Prelude is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT811, a highly selective, potent, orally bioavailable PRMT5 inhibitor; PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, and PRT3645, a brain penetrant CDK4/6 inhibitor. Additionally, Prelude is progressing a potential first-in-class SMARCA2/BRM protein degrader, with an IND expected in the second half of 2022.

For more information, visit our website and follow us on LinkedIn and Twitter.

Investor Contact:
Lindsey Trickett
Vice President, Investor Relations
240.543.7970
ltrickett@preludetx.com

Media Contact:
Helen Shik
Shik Communications
617.510.4373
Helen@ShikCommunications.com


FAQ

What conference will Prelude Therapeutics participate in on September 12, 2022?

Prelude Therapeutics will participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.

Who will represent Prelude Therapeutics at the Morgan Stanley Global Healthcare Conference?

CEO Kris Vaddi and President Dr. Jane Huang will represent Prelude Therapeutics at the Morgan Stanley Global Healthcare Conference.

What date is the fireside chat at the H.C. Wainwright Conference?

The fireside chat at the H.C. Wainwright Conference is scheduled for September 12, 2022, at 1:30 p.m. ET.

When will Prelude Therapeutics have one-on-one investor meetings?

Prelude Therapeutics will conduct one-on-one investor meetings on September 13 and September 14, 2022.

What is the focus of Prelude Therapeutics' drug development?

Prelude Therapeutics is focused on developing drug candidates that target critical cancer cell pathways.

Prelude Therapeutics Incorporated

NASDAQ:PRLD

PRLD Rankings

PRLD Latest News

PRLD Stock Data

73.75M
27.32M
9.36%
84.98%
5.55%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WILMINGTON